JP3863129B2 - モナスクスプルプレウス(Monascuspurpureus)変異体、および血圧低下活性を有する発酵産物を調製する際のその使用 - Google Patents
モナスクスプルプレウス(Monascuspurpureus)変異体、および血圧低下活性を有する発酵産物を調製する際のその使用 Download PDFInfo
- Publication number
- JP3863129B2 JP3863129B2 JP2003288306A JP2003288306A JP3863129B2 JP 3863129 B2 JP3863129 B2 JP 3863129B2 JP 2003288306 A JP2003288306 A JP 2003288306A JP 2003288306 A JP2003288306 A JP 2003288306A JP 3863129 B2 JP3863129 B2 JP 3863129B2
- Authority
- JP
- Japan
- Prior art keywords
- fermentation product
- citrinin
- monascus
- ppm
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000855 fermentation Methods 0.000 title claims description 57
- 230000004151 fermentation Effects 0.000 title claims description 57
- 230000036772 blood pressure Effects 0.000 title claims description 29
- 230000000694 effects Effects 0.000 title claims description 26
- 244000113306 Monascus purpureus Species 0.000 title claims description 25
- 235000002322 Monascus purpureus Nutrition 0.000 title claims description 25
- 229940057059 monascus purpureus Drugs 0.000 title claims description 24
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 claims description 37
- CQIUKKVOEOPUDV-UHFFFAOYSA-N citrinine Natural products OC1=C(C(O)=O)C(=O)C(C)=C2C(C)C(C)OC=C21 CQIUKKVOEOPUDV-UHFFFAOYSA-N 0.000 claims description 37
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 33
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 32
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 17
- 235000013373 food additive Nutrition 0.000 claims description 11
- 239000002778 food additive Substances 0.000 claims description 11
- 240000007594 Oryza sativa Species 0.000 claims description 10
- 235000007164 Oryza sativa Nutrition 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 244000068988 Glycine max Species 0.000 claims description 9
- 235000010469 Glycine max Nutrition 0.000 claims description 9
- 235000009566 rice Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 description 41
- 239000002609 medium Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940127088 antihypertensive drug Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- 240000000571 Nopalea cochenillifera Species 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 108010055793 gabase Proteins 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明は、モナスクス プルプレウス(Monascus purpureus)の新規変異体を提供し、この変異体は、任意のさらなる処理工程なしに、安価な天然原材料を含む固体または液体の培地中で、血圧低下活性を有する発酵産物を生成し、そしてこの産物は、少量のシトリニンを含有する。
本発明は、モナスクス プルプレウス(Monascus purpureus)を変異させ、そしてそれらをスクリーニングすることによって得られたモナスクス プルプレウス(Monascus purpureus)の変異体を提供する。この変異体は、60g/lのコメ粉末、30g/lのダイズ粉末およびMgSO4・7H2O 5g/lを含む培養培地中でインキュベートされ、発酵産物中のGABAの量が0.03mg/mlまでの場合に、シトリニンの量が1ppm未満、好ましくは0.5ppm未満、そして最も好ましくは0.15ppm未満である。
(1)GABAの定量的分析
この株の発酵液0.6mlと0.6ml LaCl3との混合物を、湯浴中にて60℃で30分間インキュベートした。この混合物を遠心分離し、そして0.1mlの上清を、水850μl中の50μlのKOH(1M)と5分間反応させた。この反応産物を遠心分離し、そして上清を保存した。
以下のHPLC分析手順を使用して、この株の発酵液中のシトリニンの量を決定した。7mlの発酵液を、3.5のpHに調整し、次いで1時間インキュベートした。3mlの酢酸エチルをこの液体に添加し、そして30分後に、酢酸エチル層を回収した。添加工程および酢酸エチル回収工程を、2回繰り返し、次いで、回収した溶液を乾燥した。
モナスクス プルプレウス(Monascus purpureus)株CCRC31499を、PDA(ジャガイモ由来の浸剤(infusion)20%、Bacto Dextrose 2%および寒天2%)の傾斜培地上に接種し、そして30℃で7日間インキュベートした。この胞子を、滅菌水で洗浄して除いた。この収集した胞子懸濁物(1ml当たり、1×107を超える胞子を含む)に、UV光を2分間照射した。連続希釈後、希釈した胞子懸濁サンプルを、PDAプレート上に広げ、そして30℃で2〜3日インキュベートした。次いで、コロニーを、コメ粉末60g/l、ダイズ粉末30g/lおよびMgSO4・7H2O 5g/lを含む培地中に接種して、変異体の安定性を試験し、そして生成されたGABAおよびシトリニンの量を決定した。
(CYA培地(スクロース30g/l、NaNO3 3g/l、K2HPO4 1.0g/l、MgSO4 0.5g/l、KCl 0.5g/l、FeSO4 0.01g/l、酵母抽出物 1g/lおよび寒天 15g/lを含有する))
7日間の培養後、コロニーは、黄みがかったオレンジ色を呈し、そして11mm〜14mmの直径を有し、そして気菌糸の色は、白色であった。
7日間の培養後、コロニーは、赤みがかったオレンジ色を呈し、そして28〜30mmの直径を有した。
(CYA培地(スクロース 30g/l、NaNO3 3g/l、K2HPO4 1.0g/l、MgSO4 0.5g/l、KCl 0.5g/l、FeSO4 0.01g/l、酵母抽出物 1g/lおよび寒天 15 g/lを含有する))
7日間の培養後、コロニーは、黄みがかったオレンジ色を呈し、そして13mm〜14mmの直径を有し、そして気菌糸は、短く、小さく、そして非常に少ししか見出されなかった。
7日間の培養後、コロニーは、赤みがかったオレンジ色を呈し、そして29〜30mmの直径を有し、そして気菌糸は、短く、小さく、そして非常に少ししか見出されなかった。
bコメ粉末60g/l、ダイズ粉末30g/lおよびMgSO4・7H2O 5g/lを含有する培養培地で培養した。
c小麦粉80g/l、酵母抽出物10g/lおよびグルタミン酸10g/lを含有する培地中で培養した。
実施例2に記載される方法に従って、異なるpH値の下で、コメ粉末80g/l、酵母抽出物10g/lおよびグルタミン酸10g/lを含有する培地中で培養した変異株の発酵液サンプルのGABAおよびシトリニンの量を分析した。結果を表2に示し、これは、異なるpH条件下で培養した変異株モナスクス プルプレウス(Monascus purpureus) M022およびM01033が、非常に少量(0.15ppm未満)のシトリニンと共に、多量のGABAを生成できたことを実証する。
aGABAの単位は、mg/mlである。
*全てのサンプル中のシトリニンの量は、検出可能な値(0.15ppm)よりも低かった。
Claims (11)
- モナスクス プルプレウス(Monascus purpureus)の変異体であって、コメ粉末60g/l、ダイズ粉末30g/lおよびMgSO4・7H2O 5g/lを含む培地中で培養した場合に、1.0ppm未満の量のシトリニンと共に、0.03mg/mlに達するGABA濃度で発酵産物を生成する、変異体であって、アメリカンタイプカルチャーコレクション(American Type Culture Collection)に受託番号PTA−4486で寄託されたモナスクス プルプレウス(Monascus purpureus) M022である、変異体。
- モナスクス プルプレウス(Monascus purpureus)の変異体であって、コメ粉末60g/l、ダイズ粉末30g/lおよびMgSO 4 ・7H 2 O 5g/lを含む培地中で培養した場合に、1.0ppm未満の量のシトリニンと共に、0.03mg/mlに達するGABA濃度で発酵産物を生成する、変異体であって、アメリカンタイプカルチャーコレクションに受託番号PTA−4485で寄託されたモナスクス プルプレウス(Monascus purpureus) M01033である、変異体。
- 発酵産物を生成するための方法であって、該方法は、請求項1または2に記載の変異体を適切な条件下で培養することによって特徴付けられ、該発酵産物は、GABAを含み、そして該発酵産物に含まれるシトリニンの量は、1.0ppm未満である、方法。
- 前記発酵産物が、血圧低下活性を有する、請求項3に記載の方法。
- 前記変異体が、固体培地または液体培地において培養される、請求項3に記載の方法。
- 前記培地のpH値が、3〜9の間である、請求項5に記載の方法。
- 前記培地のpH値が、5〜7の間である、請求項6に記載の方法。
- 前記発酵産物中のシトリニンの量が、0.5ppm未満である、請求項3に記載の方法。
- 前記発酵産物中のシトリニンの量が、0.15ppm未満である、請求項8に記載の方法。
- 前記発酵産物が、薬学的組成物の活性成分または食品添加物として使用され得る、請求項4に記載の方法。
- 血圧低下活性を有する前記成分を精製して、精製された成分を得る精製工程をさらに包含する、請求項4に記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW091118398A TWI262949B (en) | 2002-08-15 | 2002-08-15 | Monascus purpureus mutants and their use in preparing fermentation products having hypotensive activity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004073199A JP2004073199A (ja) | 2004-03-11 |
JP3863129B2 true JP3863129B2 (ja) | 2006-12-27 |
Family
ID=31989687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003288306A Expired - Lifetime JP3863129B2 (ja) | 2002-08-15 | 2003-08-06 | モナスクスプルプレウス(Monascuspurpureus)変異体、および血圧低下活性を有する発酵産物を調製する際のその使用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US7067304B2 (ja) |
JP (1) | JP3863129B2 (ja) |
TW (1) | TWI262949B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060210584A1 (en) * | 2005-03-18 | 2006-09-21 | Chiu Siu W | Method for preparing citrinin-free Monascus biomass and use of citrinin-free Monascus biomass |
KR100710497B1 (ko) * | 2005-05-18 | 2007-04-23 | 고려대학교 산학협력단 | 홍국균을 이용한 gaba 생산방법 |
CN110408545B (zh) * | 2019-03-21 | 2021-05-07 | 广东天益生物科技有限公司 | 一种紫红曲菌种及由其制备红曲粉的方法和制品 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55150898A (en) * | 1979-05-11 | 1980-11-25 | Sankyo Co Ltd | Preparation of a new physiologically active substance mb-530b |
JPS61197524A (ja) | 1985-02-15 | 1986-09-01 | Gunze Ltd | 高血圧改善剤 |
JPS62298598A (ja) | 1986-06-16 | 1987-12-25 | Gunze Ltd | モナスカス属糸状菌培養物の新規降圧画分 |
JP2590423B2 (ja) * | 1994-02-01 | 1997-03-12 | 農林水産省中国農業試験場長 | γ−アミノ酪酸を富化した食品素材 |
JPH07274978A (ja) | 1994-04-13 | 1995-10-24 | Bio Kosumosu:Kk | 紅麹色素の製造方法 |
JP4363692B2 (ja) | 1999-03-30 | 2009-11-11 | グンゼ株式会社 | 血圧降下成分を多く含む紅麹の製造方法 |
KR20010038797A (ko) | 1999-10-27 | 2001-05-15 | 김길환 | 홍국을 이용한 일산화질소 생성제 조성물 및 이를 이용한 약품 조성물 |
TWI240000B (en) * | 2000-09-29 | 2005-09-21 | Food Industry Res & Dev Inst | Monascus prupureus mutant and its use in preparing yellow pigment |
-
2002
- 2002-08-15 TW TW091118398A patent/TWI262949B/zh not_active IP Right Cessation
-
2003
- 2003-07-29 US US10/629,198 patent/US7067304B2/en not_active Expired - Lifetime
- 2003-08-06 JP JP2003288306A patent/JP3863129B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20040047842A1 (en) | 2004-03-11 |
US7067304B2 (en) | 2006-06-27 |
TWI262949B (en) | 2006-10-01 |
JP2004073199A (ja) | 2004-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11618889B2 (en) | Saccharomyces cerevisiae kwon P-1, 2, 3 which produce aldehyde dehydrogenase and glutathione | |
El-Sayed et al. | Screening, morphological and molecular characterization of fungi producing cystathionine γ-lyase | |
CN107955792B (zh) | 一种洛伐他汀高产红曲菌及其高通量筛选方法 | |
JP2020031580A (ja) | β−グルカン高産生菌株、β−グルカンの製造方法、及びβ−グルカン高産生菌株のスクリーニング方法 | |
JP3618702B2 (ja) | Monascuspurpureus変異体、および黄色色素の調製におけるその使用 | |
US20160051596A1 (en) | Novel acetobacter and gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase | |
KR101809447B1 (ko) | 류코노스톡 메센테로이드 drc1506 균주 및 이의 용도 | |
CN111000204A (zh) | 一种提高虾酱品质的发酵方法 | |
JP3863129B2 (ja) | モナスクスプルプレウス(Monascuspurpureus)変異体、および血圧低下活性を有する発酵産物を調製する際のその使用 | |
Parker et al. | Mutants of yeast with altered oxidative energy metabolism: selection and genetic characterization | |
Osaro-Matthew et al. | Screening of actinomycetes from turmeric (Curcuma longa L.) and ginger (Zingiber officinale) rhizosphere for antifungal activity | |
JP5904522B2 (ja) | アザ糖を生産する微生物 | |
JP5551354B2 (ja) | 糖アルコールの製造方法 | |
Nguyen et al. | Cultural characteristics and cordycepin production of some Cordyceps militaris strains under artificial cultivation conditions | |
CN111286500B (zh) | 一种等离子体作用结合氧限制生产辅酶q10的方法 | |
KR102359343B1 (ko) | 사카로마이세스 세레비지애 srcm102595 균주를 이용한 막걸리의 제조방법 | |
JP4434927B2 (ja) | γ−アミノ酪酸含有食品の製造方法、及びγ−アミノ酪酸高生成能を有する酵母 | |
Chayawat et al. | Pigments and anti-cholesterol agent production by Monascus kaoliang KB9 and its color mutants in rice solid cultures | |
Ghezelbash et al. | Study of polyols production by Yarrowia lipolytica in batch culture and optimization of growth condition for maximum production | |
CN100384981C (zh) | 红曲霉突变株及其于制备具降血压活性发酵产物之用途 | |
KR20150128365A (ko) | 신규한 스타터 균주 및 이를 이용한 사워도우 | |
KR20200107287A (ko) | 신규 사카로마이세스 세레비지에 nw-3 균주 및 그 용도 | |
TWI822167B (zh) | 烏龍茶醱酵物、其製造方法、含此之食品組成物及其用於製備具抗氧化及抑制血管張力素轉化酶功效之食品組成物的用途 | |
CN114214240B (zh) | 一株筑波链霉菌诱变菌株及其在联产他克莫司与双烯他克莫司中的应用 | |
CN115369054B (zh) | 一种豆粕水解物及其制备与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060822 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060913 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060927 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 3863129 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091006 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101006 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101006 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111006 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121006 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131006 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |